- Active Pharmaceutical Ingredients
- 酒石酸伐尼克兰
- Aprepitant, Fosapitant Intermediates
- 福沙匹坦双葡甲胺
- 维格列汀
- 艾氟康唑
- Luliconazole Intermediate
- 钆特酸葡胺
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- 酒石酸伐尼克兰
- 阿瑞匹坦 287930-73-8
- 阿瑞匹坦 127852-28-2
- 阿瑞匹坦 287930-75-0
- 阿瑞匹坦 200000-59-5
- 阿瑞匹坦 155742-64-6
- 阿瑞匹坦 252742-72-6
- 福沙匹坦双葡甲胺 990-91-0
- 福沙匹坦双葡甲胺 265121-01-5
- 维格列汀 207557-35-5
- 维格列汀 702-82-9
- 艾氟康唑 144230-50-2
- 艾氟康唑 133775-25-4
- 艾氟康唑 127000-90-2
- 钆特酸葡胺
- 米拉贝隆
- 卢立康唑 98873-55-3
- 卢立康唑 126534-31-4
- 硫酸阿扎那韦
- 硼替佐米 179324-87-9
- 硼替佐米 114457-94-2
- 硼替佐米 205393-22-2
- 布林佐胺
- 利伐沙 446292-08-6
- 利伐沙 446292-07-5
- 西那卡塞 1005450-55-4
- 西那卡塞 585-50-2
- Eletriptan Intermediate
- 茚达特罗 312753-53-0
- 茚达特罗 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Bortezomib intermediate
【Catalogue Number】AP0101
【CAS #】 179324-87-9
【Molecular formula】C17H29BF3NO4
【Product Introduction】(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methyl bridge-1,3 ,2-Benzodioxyborane-2-methylamine 2,2,2-trifluoroacetate, English name is (1R)-(S)-Pinanediol 1-ammonium trifluoroacetate-3-methylbutane-1-boronate , The American Chemical Abstracts Registry number is cas 179324-87-9.
Bortezomib intermediate
Alias Bortezomib Intermediate
Catalog number AP0101
CAS # 179324-87-9
Molecular formula C17H29BF3NO4
Molecular weight 379.22
Structural formula
Product introduction
CAS 179324-87-9 (aR, 3aS, 4S, 6S, 7aR) -hexahydro-3a, 8,8-trimethyl-alpha- (2-methylpropyl) -4,6-methyl bridge-1 , 3,2-benzodioxorane-2-methylamine 2,2,2-trifluoroacetate, the English name is (1R)-(S) -Pinanediol 1-ammonium trifluoroacetate-3-methylbutane-1 -boronate, American Chemical Abstracts Registry Number cas 179324-87-9.
This product salt (cas 179324-87-9) is an intermediate of bortezomib. Bortezomib is a reversible inhibitor of 26S proteasome chymotrypsin-like activity in mammalian cells. Proteolysis can affect the cascade of multilevel signals in the cell, and this damage to the normal intracellular environment can lead to cell death. Inhibition of the 26S proteasome prevents hydrolysis of specific proteins. In vitro tests have proven that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor model in vivo tests have demonstrated that bortezomib can delay tumor growth, including multiple myeloma. Bortezomib can be used in the treatment of patients with multiple myeloma.
VIWIT 沪ICP备12014533号-1
